We are getting closer to finding out if at least two experimental COVID-19 vaccines work.
Pfizer expects to have early data showing if the vaccine works by the end of October. It will then take several more weeks to evaluate longer-term safety.
[Ads /]
Moderna has enrolled all 30,000 volunteers needed for its trial. They expect results in November and hope to apply for emergency use authorization in December.
RELATED: FDA approves Gilead's remdesivir to treat COVID-19
Both AstraZeneca and Johnson & Johnson announced they are re-starting their trials in the U.S. They had been put on hold due to potential safety concerns but are now cleared to resume.
[Ads /]
Early doses of the vaccine will go to people who are high-risk, which includes health care workers and people who live and work in long-term care facilities.
Vaccines for the general population likely will not be available until sometime later next year.